Physician

Amol Nanak Rakkar, M.D.

According to 2025 Medicare claims, Amol Rakkar, M.D. (NPI: 1336160241) practices hematology/oncology in the Phoenix-Mesa-Chandler, AZ market, with the plurality of this provider's patient population coming from Maricopa, AZ. This provider's primary affiliated billing organization is PALO VERDE HEMATOLOGY ONCOLOGY LTD. (NPI: 1447272372; TIN: 860416050) and primary practice location at 85304-6255.

Rakkar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 860 traditional Medicare patients, billed 267,506 HCPCS/CPT codes, and received $4,708,100 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 3,112 prescription claims across 566 beneficiaries totaling $10,179,207 in drug costs, led by Xtandi (Enzalutamide). 2019 DME data shows 43 claims. Open Payments data shows 157 records totaling $115,010. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,835,183 to $10,179,207. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	841	432,904	$4,860,072
2016	908	372,103	$4,235,669
2017	910	269,832	$4,116,859
2018	933	359,328	$4,594,325
2019	957	379,945	$5,317,764
2020	844	397,254	$6,649,096
2021	823	325,372	$5,369,858
2022	791	259,478	$4,417,965
2023	812	273,490	$4,367,265
2024	860	267,506	$4,708,100

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	438	2,467	$1,835,183
2016	432	2,598	$2,145,287
2017	456	2,438	$2,178,528
2018	470	2,637	$3,499,226
2019	495	2,464	$4,222,193
2020	528	2,684	$4,478,505
2021	513	2,725	$4,990,793
2022	460	2,558	$5,773,172
2023	478	2,410	$6,819,886
2024	566	3,112	$10,179,207

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	61	$7,699
2019	N/R	43	$4,514
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	176	176	$156
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	497	1,106	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	147	164	$64
36415	Insertion of needle into vein for collection of blood sample	357	1,106	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	406	1,679	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	193	5,790	$2,569,554
Cabometyx	Cabozantinib S-Malate	80	2,400	$1,958,828
Pomalyst	Pomalidomide	34	945	$664,792
Ibrance	Palbociclib	29	812	$445,508
Venclexta	Venetoclax	28	810	$394,530

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	130	$3,290	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	27	$111,720	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amol Nanak Rakkar, M.D.?

Tedicare shows public-source Medicare data for Amol Nanak Rakkar, M.D. (NPI 1336160241), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amol Nanak Rakkar, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Amol Nanak Rakkar, M.D.?

Amol Nanak Rakkar, M.D. is linked to PALO VERDE HEMATOLOGY ONCOLOGY LTD. (billing NPI 1447272372) in the available physician profile data.

Does Amol Nanak Rakkar, M.D. have Open Payments data?

Amol Nanak Rakkar, M.D. has 157 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.